Astragalus Injection for Hypertensive Renal Damage: A Systematic Review

Abstract EN

Objective.

To evaluate the effectiveness of astragalus injection (a traditional Chinese patent medicine) for patients with renal damage induced by hypertension according to the available evidence.

Methods.

We searched MEDLINE, China National Knowledge Infrastructure (CNKI), Chinese VIP Information, China Biology Medicine (CBM), and Chinese Medical Citation Index (CMCI), and the date of search starts from the first of database to August 2011.

No language restriction was applied.

We included randomized controlled trials testing astragalus injection against placebo or astragalus injection plus antihypertensive drugs against antihypertensive drugs.

Study selection, data extraction, quality assessment, and data analyses were conducted according to the Cochrane review standards.

Results.

5 randomized trials (involving 429 patients) were included and the methodological quality was evaluated as generally low.

The pooled results showed that astragalus injection was more effective in lowering β2-microglobulin (β2-MG), microalbuminuria (mAlb) compared with placebo, and it was also superior to prostaglandin in lowering blood urea nitrogen (BUN), creatinine clearance rate (Ccr).

There were no adverse effects reported in the trials from astragalus injection.

Conclusions.

Astragalus injection showed protective effects in hypertensive renal damage patients, although available studies are not adequate to draw a definite conclusion due to low quality of included trials.

More rigorous clinical trials with high quality are warranted to give high level of evidence.